IDO1 and lung cancer: In our recent preclinical studies, dual inhibition of IDO1 and TDO2 with the novel agent AT-0174 effectively reduced KYN levels, increased tumor infiltration with natural killer cells, and reduced regulatory T cells in cisplatin-resistant lung cancer models (38).